Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. (September 2017)
- Record Type:
- Journal Article
- Title:
- Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. (September 2017)
- Main Title:
- Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma
- Authors:
- Lohneis, Philipp
Sinn, Marianne
Bischoff, Sven
Jühling, Anja
Pelzer, Uwe
Wislocka, Lilianna
Bahra, Marcus
Sinn, Bruno V.
Denkert, Carsten
Oettle, Helmut
Bläker, Hendrik
Riess, Hanno
Jöhrens, Korinna
Striefler, Jana K. - Abstract:
- Abstract: Background: We studied the prognostic effect of CD3-, CD8- and CD103-positive T lymphocytes in a cohort of 165 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the treatment group (adjuvant gemcitabine) and the untreated control group of the CONKO-001 study. Methods: Immunohistochemical stainings on tissue microarrays (TMAs) against CD3, CD8 and CD103 were performed according to standard procedures. Results: A high number of CD8-positive lymphocytes were significantly and independently associated with longer disease-free survival (DFS) and overall survival (OS) in the overall study population. Median DFS/OS were 7.4/18.1 months for patients with a low number of CD8-positive intratumoural lymphocytes ( ≤ 42 per 1 mm tissue core) and 12.7/25.2 months for patients with high numbers (>42 per 1-mm tissue core; p = 0.008/0.020; HR 0.62/0.65). The ratio of intraepithelial to total CD103-positive lymphocytes, but not total numbers of CD103-positive lymphocytes or CD103-positive intraepithelial lymphocytes, was associated with significantly improved DFS and OS in the overall study population (p = 0.022/0.009). Median DFS/OS was 5.9/15.7 for patients with a ratio of intraepithelial to total CD103-positive intratumoural lymphocytes higher than 0.3 and 11.6/24.7 for patients with a lower ratio. Conclusion: T-lymphocyte subpopulations might be prognostic in resectable PDAC but need standardization and verification by further studies. Highlights: TheAbstract: Background: We studied the prognostic effect of CD3-, CD8- and CD103-positive T lymphocytes in a cohort of 165 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the treatment group (adjuvant gemcitabine) and the untreated control group of the CONKO-001 study. Methods: Immunohistochemical stainings on tissue microarrays (TMAs) against CD3, CD8 and CD103 were performed according to standard procedures. Results: A high number of CD8-positive lymphocytes were significantly and independently associated with longer disease-free survival (DFS) and overall survival (OS) in the overall study population. Median DFS/OS were 7.4/18.1 months for patients with a low number of CD8-positive intratumoural lymphocytes ( ≤ 42 per 1 mm tissue core) and 12.7/25.2 months for patients with high numbers (>42 per 1-mm tissue core; p = 0.008/0.020; HR 0.62/0.65). The ratio of intraepithelial to total CD103-positive lymphocytes, but not total numbers of CD103-positive lymphocytes or CD103-positive intraepithelial lymphocytes, was associated with significantly improved DFS and OS in the overall study population (p = 0.022/0.009). Median DFS/OS was 5.9/15.7 for patients with a ratio of intraepithelial to total CD103-positive intratumoural lymphocytes higher than 0.3 and 11.6/24.7 for patients with a lower ratio. Conclusion: T-lymphocyte subpopulations might be prognostic in resectable PDAC but need standardization and verification by further studies. Highlights: The prognostic effects of lymphocyte subpopulations were studied in patients with pancreatic carcinoma (PDAC). A high number of CD8-positive lymphocytes are associated with longer in PDAC. The ratio of intraepithelial to total CD103-positive lymphocytes is associated with longer DFS and OS in PDAC. … (more)
- Is Part Of:
- European journal of cancer. Volume 83(2017)
- Journal:
- European journal of cancer
- Issue:
- Volume 83(2017)
- Issue Display:
- Volume 83, Issue 2017 (2017)
- Year:
- 2017
- Volume:
- 83
- Issue:
- 2017
- Issue Sort Value:
- 2017-0083-2017-0000
- Page Start:
- 290
- Page End:
- 301
- Publication Date:
- 2017-09
- Subjects:
- Pancreatic cancer -- Gemcitabine -- Tumour-infiltrating lymphocytes -- T lymphocytes -- CD3 -- CD103 -- CD8
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Cancer
Tumors
Electronic journals
Periodicals
Electronic journals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/09598049 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=2879 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09598049 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09598049 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.ejca.2017.06.016 ↗
- Languages:
- English
- ISSNs:
- 0959-8049
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.725100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4616.xml